Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10876923 | 0.98 | ALDH1A1 (0.31) | NOTUMAHR | |
| Hydrochloric Acid SCHEMBL10818417 | 0.87 | — | — | |
| SCHEMBL10863938 | 0.79 | NOTUM (0.31) | NOTUM | |
| SCHEMBL8891031 | 0.79 | GAA (0.33) | — | |
| Clonidine SCHEMBL5982 | 0.75 | MAPT (0.36) | AHR | |
| Clonidine SCHEMBL1369983 | 0.75 | MAPT (0.36) | AHR | |
| SCHEMBL10607540 | 0.75 | GAA (0.30) | — | |
| SCHEMBL10973840 | 0.75 | CD44 (0.33) | — | |
| Clonidine SCHEMBL10972183 | 0.73 | ADRA2A (0.36) | AHR | |
| Clonidine SCHEMBL40751 | 0.73 | ADRA2A (0.36) | AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0081924-B1 | TOPICAL COMPOSTIONS FOR LOWERING INTRAOCULAR PRESSURE | ALCON LABORATORIES, INC. (US) | 1986-02-19 | — | — | EP | claimed |
| US-6747051-B2 | BLADDER UROGENITAL DISORDERS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-08 | — | — | US | disclosed |
| CN-1471514-A | Novel M-amino-phenylimino-imidazolidone derivatives for treating urinary incontinence | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-01-28 | — | — | CN | disclosed |
| US-20030158420-A1 | m-Amino-phenylimino-imidazolidine derivatives for treaing urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2003-08-21 | — | — | US | disclosed |
| US-6602897-B2 | For example, 2-((2-bromo-3-chloro-5-dimethylamino-6-methylphenyl)imino)imid azolidine | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-05 | — | — | US | disclosed |
| EP-1328517-A2 | NOVEL M-AMINO-PHENYLIMINO-IMIDAZOLIDINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | Boehringer Ingelheim Pharma KG (DE) | 2003-07-23 | — | — | EP | disclosed |
| US-20020161031-A1 | m-amino-phenylimino-imidazolidine derivatives for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-10-31 | — | — | US | disclosed |
| WO-2002032876-A2 | NOVEL M-AMINO-PHENYLIMINO-IMIDAZOLIDINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-25 | — | — | WO | disclosed |
| EP-0070084-A2 | Imidazoline derivatives | BEECHAM GROUP PLC (GB) | 1983-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161031-A1 | m-amino-phenylimino-imidazolidine derivatives for treating urinary incontinence | RXFP1, RXFP3, PRMT1 | NOTUM 3633/4885AHR 951/4885 |
| US-20030158420-A1 | m-Amino-phenylimino-imidazolidine derivatives for treaing urinary incontinence | HRH2, RXFP3, AREG | NOTUM 3669/4885AHR 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.